11. Tumor-Agnostic

11.1. Clinical Trial
- 11.1.1. Solid Tumors
11.2. Supportive Cancer Care
11.3. Translational Research
11.4. Basic Research
- 11.4.1. Immunological

11.0 Tumor-Agnostic
11.1 Clinical Trial
11.1.1.1 Solid Tumors
Locally Advanced or Metastatic
Specific Selection Criteria: NTRK1/2/3, ROS1, ALK
First-line or Second-line treatment: Phase 2		Targeted Therapy (ALK Inhibitor)
STARTRK-2 (Protocol ID: RXDX-101-02): An open-Label, multicenter, global phase 2 basket study of entrectinib for the treatment of patients with locally advanced or metastatic solid tumors that harbor NTRK1/2/3, ROS1, or ALK gene rearrangements.	Key Inclusion Criteria: Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement. Prior anticancer therapy is allowed.	Entrectinib (ALK Inhibitor)	Dr. Thomas Yau	Department of Medicine (Medical Oncology)	medicaloncology@hku.hk	2255 5582
11.1.1.2 Solid Tumors
Locally Advanced or Metastatic
Second, Third or Fourth-line treatment: Phase 2		Targeted Therapy (Anti-HRS7-SN38 ADC)
TROPiCS-03 (Protocol ID: IMMU-132-11): A phase 2, open-label study of sacituzumab govitecan (IMMU-132) in subjects with metastatic solid tumours.	Key Inclusion Criteria: Histologically documented metastatic (M1, Stage IV) or locally advanced solid tumors NSCLC (adenocarcinoma or SCC) that has progressed after prior platinum-based chemotherapy and programmed death-(ligand) 1 (PD-(L)1) directed therapy. HNSCC that has progressed after prior platinum-based chemotherapy and anti-PD-(L)1 directed therapy. No more than 3 prior lines of systemic treatment is allowed. Endometrial carcinoma that has progressed after prior platinum-based chemotherapy and anti-PD-(L)1 directed therapy. No more than 3 prior lines of systemic treatment is allowed. Extensive stage SCLC that has progressed after prior platinum-based chemotherapy and PD-(L)1 directed therapy. No more than one prior line of systemic treatment is allowed (re-challenge with the same initial regimen is not allowed).	Sacituzumab Govitecan-hziy (SG) (Anti-HRS7-SN38 ADC)	Dr. Joanne Chiu	Department of Medicine (Medical Oncology)	jwychiu@hku.hk	2255 5582
11.1.1.3 Solid Tumors
Locally Advanced or Metastatic, Unresectable
Second-line treatment: Phase 1/2		Targeted Therapy (Anti-ROR2 ADC), Immunotherapy (Anti-PD-1 Antibody)
A phase 1/2 dose escalation and dose expansion study of BA3021 alone and in combination with nivolumab in patients with advanced solid tumors.	Key Inclusion Criteria: Patients must have histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy.	BA3021 (Anti-ROR2 ADC) +/- Nivolumab (Anti-PD-1 monoclonal Antibody)	Dr. Thomas Yau	Department of Medicine (Medical Oncology)	medicaloncology@hku.hk	2255 5582

11.1.1.4 Solid Tumors
Advanced, Metastatic, Non-resectable, Recurrent
Specific Selection Criteria: Tumor association with MYC oncogene
Second or Subsequent-line treatment: Phase 1/2		mRNA therapeutic, Targeted Therapy (tyrosine kinase inhibitor), Immunotherapy (Anti-PD-1/ PD-L1 antibody)
Study Title	Main Inclusion/Exclusion	Investigational Product	Principal Investigator	Department	Email	Contact number
A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene.	Key Inclusion Criteria: Participants with metastatic, advanced (non-resectable), or recurrent solid tumor who progressed on, relapsed after, are refractory to, or intolerant of standard of care (only applicable to Part 1 escalation). Participants with BCLC Stage B (intermediate stage) or C (advanced stage), Child-Pugh A hepatocellular carcinoma who is not amenable to locoregional therapy, refractory to locoregional therapy or not amenable to curative treatment approach. Progressed on, have relapsed after, be refractory to, or be intolerant of at least 1 prior systemic therapy, and without available subsequent standard of care.	OTX-2002 (mRNA therapeutic) Vs OTX-2002 + TKI 1 Vs OTX-2002 + TKI 2 Vs OTX-2002 + Anti-PD-1/L1 antibody	Dr. Thomas Yau	Department of Medicine (Medical Oncology)	medicaloncology@hku.hk	2255 5582

11.1.1.5 Solid Tumors
Locally Advanced or Metastatic
After all standard treatment: Phase 1/2		Targeted Therapy (Anti-ROR2 ADC), Immunotherapy (PD-1 Inhibitor)
Ph2 (Protocol ID: BA3021-001): A phase 1/2 safety and efficacy dose escalation / dose expansion study of a CAB-ROR2-ADC, alone and in combination with a PD-1 inhibitor, in patients with advanced solid tumors (Ph1) and melanoma and NSCLC patients (Ph2).	Key Inclusion Criteria: Locally advanced unresectable or metastatic solid tumor and have failed all available standard of care (SoC) therapy and for whom no curative therapy is available or who are not eligible, intolerant to or refuse standard therapy.	BA3021 (Anti-ROR2 ADC) +/- BA3021 + PD-1 inhibitor (PD-1 inhibitor)	Dr. Thomas Yau	Department of Medicine (Medical Oncology)	medicaloncology@hku.hk	2255 5582
11.1.1.6 Solid Tumors
Locally Advanced or Metastatic
After all standard treatment: Phase 1		Arginine-depleting enzyme
A 2-part, first-in-patient, open-label, dose-escalation and expansion cohort study of NEI-01 as monotherapy in patients with advanced solid tumors or relapsed/refractory acute myeloid leukemia.	Key Inclusion Criteria: Histologically or cytologically confirmed diagnosis of any locally advanced or metastatic solid tumor. (Part 1 and 2). Histologically or cytologically confirmed diagnosis of relapsed or refractory AML as defined by World Health Organisation (WHO) classification. (Part 2).	NEI-01 (Arginine-depleting enzyme)	Dr. Thomas Yau	Department of Medicine (Medical Oncology)	medicaloncology@hku.hk	2255 5582
11.1.1.7 Solid Tumors
Advanced or Metastatic, Unresectable
Specific Selection Criteria: MTAP-null
After all standard treatment: Phase 1		Targeted Therapy (PRMT5 Inhibitor), Chemotherapy
MTAP (Protocol ID: 20210023): A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors.	Key Inclusion Criteria: Histologically confirmed metastatic or locally advanced solid tumor not amenable to curative treatment with surgery and/or radiation.	AMG 193 (PRMT5 inhibitor) alone + docetaxel (Chemo)	Dr. Aya El Helali	Department of Clinical Oncology	ahelali@hku.hk	Angela IU 2255 5124
11.1.1.8 Solid Tumors
Locally Advanced or Metastatic, Unresectable
After all standard treatment: Phase 1		Immunotherapy (Anti-CTLA4 monoclonal antibody)
A study evaluating the safety, tolerance and anti-tumor activity of a study drug in subjects with advanced solid tumors	Key Inclusion Criteria: Confirmed advanced solid tumors that have progressed after treatment with standard therapies.	HBM4003 (Anti-CTLA4 monoclonal antibody)	Dr. Thomas Yau	Department of Medicine (Medical Oncology)	medicaloncology@hku.hk	2255 5582
11.1.1.9 Solid Tumors
Metastatic, Unresectable
Specific Selection Criteria: Gene Alteration
After all standard treatment: Phase 1		Targeted Therapy (FGFR2 inhibitor)
REFOCUS (Protocol ID: RLY-4008-101): A first-in-human study of highly selective FGFR2 Inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma (ICC) and other advanced solid tumors.	Key Inclusion Criteria: Histologically or cytologically confirmed unresectable or metastatic solid tumor. Documented FGFR2 gene fusion, mutation, or amplification. Disease that is refractory to standard therapy, disease that has not adequately responded to standard therapy, disease for which standard or curative therapy does not exist.	RLY-4008 (FGFR2 inhibitor)	Dr. Joanne Chiu	Department of Medicine (Medical Oncology)	jwychiu@hku.hk	2255 5582

11.0 Tumor-Agnostic
11.2.1 Supportive Cancer Care
Early Stage
Specific Selection Criteria: Completed primary treatment of curative intent for at least 12 months
Study Title	Main Inclusion/Exclusion	Principal Investigator	Department	Email	Contact number
A Technology-based Intervention for Promoting Physical Activity among Post-treatment Cancer Survivors.	Key Inclusion Criteria: Completion of primary treatment of curative intent for at least 12 months. No metastasis. No recurrence. Not meeting the recommended PA guideline. Access to Internet. Able to read Chinese and communicate in Cantonese or Putonghua. Screened by a nurse as no contraindications for engaging in unsupervised exercise using a risk screening tool. Key Exclusion Criteria: Have a psychiatric disorder. Significant cognitive impairment. A history of more than one cancer.	Dr Denise Shuk Ting Cheung	School of Nursing	denisest@hku.hk	3917 6673
11.2.4 Supportive Cancer Care
Early Stage
Specific Selection Criteria: Completed adjuvant treatments within the past 12 months
How to prevent lost in transition? - Adaptive randomised controlled trial of a self-management-based survivorship intervention for Chinese cancer survivors	Key Inclusion Criteria: Are recently diagnosed with non-metastatic cancer(s). Have had surgery. Have completed adjuvant treatments within the past 12 months. Key Exclusion Criteria: Metastatic cancer.	Dr. Wendy WT Lam	School of Public Health	wwtlam@hku.hk	3917 9878
11.2.5 Supportive Cancer Care
Early Stage
Specific Selection Criteria: Aged ≥65, Completed primary treatment with curative intent for 3-12 months
Development of a Mobile Chat-based Exercise Counselling Intervention (ChatEx) for Increasing and Maintaining Exercise Behaviour in Older Cancer Survivors.	Key Inclusion Criteria: Aged ≥65. Diagnosed with stage I-III non-metastatic cancer. Completed primary treatment with curative intent for 3-12 months with no recurrence or occurrence of additional cancers. Can communicate in Cantonese or Mandarin. Have an ECOG performance status of 0 or 1. Own a smartphone and proficient in using IM. Key Exclusion Criteria: Contraindications to unsupervised exercise Already performing ≥150 minutes of moderate or 75 minutes of vigorous aerobic exercise and two sessions of resistance exercise per week (already meeting recommended exercise guidelines).	Dr Denise Shuk Ting Cheung	School of Nursing	denisest@hku.hk	3917 6673
11.2.6 Supportive Cancer Care
Early Stage
Specific Selection Criteria: Aged ≥ 65 years, completed primary treatment with curative intent for 6 months to 5 years
Study Title	Main Inclusion/Exclusion	Principal Investigator	Department	Email	Contact number
Winding the Clock Backward: An Experience-Based Co-Design Approach to Inform the Development of a Brief Reminiscence-Based Intervention to Improve Cognitive Function in Older Cancer Survivors.	Key Inclusion Criteria: Aged ≥ 65 years. Diagnosed with stage I-III non-metastatic cancer. Completed primary treatment with curative intent (surgery, chemotherapy, and/or radiation therapy) 6 months to 5 years prior to baseline assessments with no recurrence or occurrence of additional cancers. Identified as mild cognitive impairment by the HK-MoCA 5-Min Protocol cognitive assessment (≤ 7th age and education corrected percentile cutoff score). Key Exclusion Criteria: Inadequate written and verbal Cantonese and/or English comprehension for study activities. Been diagnosed with dementia.	Dr Mu-Hsing Ho	School of Nursing	mhbho@hku.hk	3910 2787
11.2.7 Supportive Cancer Care
Early Stage
Specific Selection Criteria: Aged ≥65, completed primary treatment with curative intent for 6 months to 5 years
Reversing Frailty Status among Post-treatment Older Cancer Survivors using Baduanjin Qigong: A Randomized Controlled Trial.	Key Inclusion Criteria: Aged ≥65. Diagnosed with stage I-III non-metastatic cancer. Completed primary treatment with curative intent (surgery, chemotherapy, and/or radiation therapy) 6 months to 5 years prior to baseline assessments with no recurrence or occurrence of additional cancers. Classified as pre-frail or frail based on Fried frailty criteria. Can communicate in Cantonese or Putonghua. Written informed consent. Key Exclusion Criteria: Regular qigong training or other mind body intervention (once or more per week) within the previous 6 months. Medical conditions affecting mobility, predisposing to falls, or precluding qigong practice.	Dr Denise Shuk Ting Cheung	School of Nursing	denisest@hku.hk	3917 6673
11.2.8 Supportive Cancer Care
Early Stage
Specific Selection Criteria: Completed neurotoxic chemotherapy, experience neuropathy
Improving Chemotherapy-induced Peripheral Neuropathy in Cancer Patients Using a Combined Qigong and Self-administered Acupressure Intervention: A Randomized Controlled Trial	Key Inclusion Criteria: Completed neurotoxic chemotherapy at least 1 month prior to enrolment. Experiencing CIPN. Participants taking anti-neuropathy medications will also be included if on a fixed dosage regimen in the past three months. Key Exclusion Criteria: Have psychiatric disorders or conditions that preclude practicing qigong or acupressure. Have regularly engaged in qigong or acupressure (>once per week) in the previous 6 months. Are receiving acupuncture, are pregnant or lactating. Have any infection/injury/ulcers around the acupoints, or had peripheral neuropathy before chemotherapy.	Dr Denise Shuk Ting Cheung	School of Nursing	denisest@hku.hk	3917 6673
11.2.9 Supportive Cancer Care
Advanced Stage
Specific Selection Criteria: Recently diagnosed with advanced cancer
Managing fear of cancer progression metacognition-based Vs supportive-expressive based approaches: A randomized controlled trial	Key Inclusion Criteria: Recently diagnosed with advanced cancer. Fear of Progression Questionnaire (FoP-Q-SF) score ≥ 24. Key Exclusion Criteria: Depression or psychosis, and are currently receiving psychological treatment.	Dr. Wendy WT Lam	School of Public Health	wwtlam@hku.hk	3917 6673

11.0 Tumor-Agnostic
11.3 Translational Research
Study Title				Principal Investigator		Department		Email	Contact number
Clinical Translational Study on The Treatment of Malignant Tumors with Novel Tumor Killer Cell CAR-ITNK				Prof. Pengtao Liu		School of Biomedical Sciences		pliu88@hku.hk	Prof. Pengtao Liu 2831 5407
11.0 Tumor-Agnostic
11.4.1 Basic Research
Study Title	Main Inclusion/Exclusion		Investigational Product	Principal Investigator		Department		Email	Contact number
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients.	Key Inclusion Criteria: Cancer Patients: Normal (non-cancer) controls: Scheduled to receive any kind of therapy or no cancer therapy. Without a history of cancer except for cured skin cancer.		Any kind of therapy or healthy control.	Prof. Feng-ming Spring KONG		Department of Clinical Oncology		kong0001@hku.hk	Eunice Xie 2255 5123
11.4.2 Basic Research
Study Title		Principal Investigator			Department		Email		Contact number
Structure-activity relationship of Andrographolide derivatives in the treatment of cancer.		Dr. George P.H. Leung			Department of Pharmacology and Pharmacy		gphleung@hku.hk		3917 6861
11.4.3 Basic Research
Functional characterization of PIK3R1 nSH2 domain mutations for precision cancer medicine.		Dr Lydia Wai Ting Cheung			School of Biomedical Sciences		lydiacwt@hku.hk		Dr Lydia Wai Ting Cheung 3917 6908
11.4.4 Basic Research
p85β as an activator of BCLAF1 for oncogenicity		Dr Lydia Wai Ting Cheung			School of Biomedical Sciences		lydiacwt@hku.hk		Dr Lydia Wai Ting Cheung 3917 6908
11.4.5 Basic Research
Characterization of PIK3R1 nSH2 domain mutations in cancer		Dr Lydia Wai Ting Cheung			School of Biomedical Sciences		lydiacwt@hku.hk		Dr Lydia Wai Ting Cheung 3917 6908
11.4.6 Basic Research
Investigating phosphatidylinositol lipid signaling at the cancer invadosome		Dr. Cheng-Han Yu			School of Biomedical Sciences		chyu1@hku.hk		Dr. Cheng-Han Yu 3917 9205
11.4.7 Basic Research
Investigating the role of dynamin2-mediated integrin endocytosis in cancer cell migration and invadosome signaling		Dr. Cheng-Han Yu			School of Biomedical Sciences		chyu1@hku.hk		Dr. Cheng-Han Yu 3917 9205
11.4.8 Basic Research
Development of novel nanomedicine to enhance cancer chemotherapy response		Dr Lydia Wai Ting Cheung			School of Biomedical Sciences		lydiacwt@hku.hk		Dr Lydia Wai Ting Cheung 3917 6908
11.4.9 Basic Research
Defining the transcriptional network for oncogenesis in PIK3R2-amplified tumors		Dr Lydia Wai Ting Cheung			School of Biomedical Sciences		lydiacwt@hku.hk		Dr Lydia Wai Ting Cheung 3917 6908
11.4.10 Basic Research
Role of BTRC mediated-ubiquitination in DNA damage response and associated drug sensitivity		Dr Lydia Wai Ting Cheung			School of Biomedical Sciences		lydiacwt@hku.hk		Dr Lydia Wai Ting Cheung 3917 6908
11.4.11 Basic Research
Characterisation of the role of long non-coding RNA, NORAD on HBX mediated chromosome instability.		Dr Yick Pang Ching			School of Biomedical Sciences		ypching@hku.hk		Dr Yick Pang Ching 3917 9434
11.4.12 Basic Research
Exploiting the roles of centrosomal linker in cancer formation (CRF)		Dr Yick Pang Ching			School of Biomedical Sciences		ypching@hku.hk		Dr Yick Pang Ching 3917 9434
11.4.13 Basic Research
Regulation of a putative tumor suppressor, TAX1 binding protein 2 (TAX1BP2) by a centrosomal salt-inducible kinase		Dr Yick Pang Ching			School of Biomedical Sciences		ypching@hku.hk		Dr Yick Pang Ching 3917 9434
11.4.14 Basic Research
Regulation of centrosome duplication by Aurora A phosphorylation in cancer.		Dr Yick Pang Ching			School of Biomedical Sciences		ypching@hku.hk		Dr Yick Pang Ching 3917 9434
11.4.15 Basic Research
A high throughput platform for screening and sorting single cancer cells based on cellular mechanical properties		Dr Joshua Wing Kei Ho			School of Biomedical Sciences		jwkho@hku.hk		Dr Joshua Wing Kei Ho 3917 9512
11.4.16 Basic Research
Exploiting the potential of cyro-EM for structure-based drug design: Targeting ATM for therapeutic intervention in cancer and degenerative diseases		Prof. Michael Shing Yan Huen			School of Biomedical Sciences		huen.michael@ hku.hk		Prof. Michael Shing Yan Huen 3917 6868
11.4.17 Basic Research
Deciphering Cancer Cell Resistance to Radiotherapy		Prof. Michael Shing Yan Huen			School of Biomedical Sciences		huen.michael@ hku.hk		Prof. Michael Shing Yan Huen 3917 6868
11.4.18 Basic Research
Understanding Cancer Cell Resistance to Chemotherapeutics		Prof. Michael Shing Yan Huen			School of Biomedical Sciences		huen.michael@ hku.hk		Prof. Michael Shing Yan Huen 3917 6868
11.4.19 Basic Research
Laboratory for Synthetic Chemistry and Chemical Biology		Prof. Chi Ming Che			School of Biomedical Sciences		stefma@hku.hk		Prof. Chi Ming Che 2859 2154
11.4 Basic Research
11.4.1.1 Immunological
Defining the molecular switch of anti-cancer type 2 innate lymphoid cells 2 (ILC2s)		Dr. Rio Ryohichi Sugimura			School of Biomedical Sciences		rios@hku.hk		Dr Rio Ryohichi Sugimura 3917 9269
11.4.1.2 Immunological
Defining the molecular landscape of tumor-associated macrophages (TAMs) at the single-cell level		Dr. Rio Ryohichi Sugimura			School of Biomedical Sciences		rios@hku.hk		Dr Rio Ryohichi Sugimura 3917 9269
11.4.1.3 Immunological
Precision modeling of the immune cell interaction with cancer cells and vasculature with single-cell quantitative imaging		Dr. Rio Ryohichi Sugimura			School of Biomedical Sciences		rios@hku.hk		Dr Rio Ryohichi Sugimura 3917 9269
11.4.1.4 Immunological
Smart polymer-peptide hybrid nanovaccines with triggered and multiple delivery of neoantigens and adjuvants for cancer immunotherapy		Dr Clive Yik Sham Chung			School of Biomedical Sciences		cyschung@hku.hk		Dr Clive Yik Sham Chung 3917 9172
11.4.1.5 Immunological
The role of Type I interferons-induced lipid peroxidation in CD8+T cell exhaustion and cancer immunotherapy resistance		Dr Heidi Guang Sheng Ling			School of Biomedical Sciences		gsling@hku.hk		Dr Heidi Guang Sheng Ling 3917 9077

Cancer Research in HKUMed11. Tumor-Agnostic

Cancer Research in HKUMed
11. Tumor-Agnostic